World’s First Ever Generic of Sofosbuvir Tablet Launched at 99% discount price in Bangladesh Market. On 03 February 2015, Incepta Pharmaceuticals Ltd launched the revolutionary oral drug Sofosbuvir for the treatment of Hepatitis C.
It is the world’s first-ever generic version of the drug Sofosbuvir and its brand name is Hopetavir. Incepta has beaten to the market a number of larger Indian competitors in the launching of generic Sofosbuvir tablets.
Previously, treatment of Hepatitis C was limited to Interferon alfa only. It is an injectable drug and thus is associated with many limitations such as low efficacy rate, patient compliance, side effects, high costs, etc. With the launching of Sofosbuvir, these limitations have now been minimized to a great extent. Sofosbuvir tablet shows a greater than 90% efficacy rate, being an oral drug patient compliance has improved and it is now a more affordable treatment option.
Incepta Pharmaceuticals have launched this generic at almost 99% discount price of the innovator’s drug. Initially, Incepta launched this drug in the Bangladesh market. To date, very few well-controlled studies have been performed regarding the prevalence of hepatitis C in Bangladesh. In these studies, 0.8-1% people of the total population have been found to be carriers of the hepatitis C virus.
Globally more than 170 million people are infected with the fatal disease hepatitis C. In the near future, the company aims to sell the drug overseas, including parts of Southeast Asia and Africa. Bloomberg has reported that the World Health Organization (WHO) is considering reviewing Hopetavir under its prequalification program, which could make the drug available in countries where innovator brand lacks patent protection and to humanitarian groups such as Médecins Sans Frontières (MSF).
Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established in the year 1999. The company has a very big manufacturing facility located at Savar, 35 kilometers away from the center of the capital city Dhaka. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid-filled hard gelatin capsules, lyophilized injections, human vaccine, etc. Since its inception, Incepta has been launching new and innovative products in order to fulfill the unmet demand of the medical community. The focus has been to bring more new technologically advanced molecules to this country.